Immune Therapeutics, Inc.
IMUN · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.11 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.28% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | -12.18 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 14.91% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.03 | 0.62 | 0.64 | -1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 103.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | -2.71 |
| Interest Coverage | 0.00 | 0.00 | -26.71 | -9.66 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |